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EDITORIAL
“The Best-Laid Plans . . . Often go Awry . . .”
James J. Urbanic, MD,* Brian Lally, MD,† and A. William Blackstock, MD*
This phrase “The Best-Laid Plans . . . Often go Awry . . .” is adapted from a line in thepoetry of Robert Burns—“To a Mouse.” Here, it seems apropos as we consider the
work by Arrieta et al.1 Alas, our ability in the last decade to improvise better therapies for
patients with inoperable stage III non-small cell lung cancer, has been limited. Here, the
investigators attempt to combine a potent radiation sensitizer, gemcitabine, with a
definitive course of thoracic radiation. In doing so, the authors observed an encouraging
overall response rate of 68% and a provocative median survival of 21 months. Although
this study is limited to 19 patients, the results would suggest this combination may have
activity. Unfortunately, the authors report that 32% of patients experienced a grade 3 to
5 pulmonary toxicity. Although we can debate what is an acceptable level of toxicity–in
a cohort of patients with a very limited possibility of cure, what we must accept is the very
narrow therapeutic ratio when combining gemcitabine and a course of definitive thoracic
radiation. As reflected in Figure 1, with the addition of a radiation sensitizer, we hope to
increase the tumor-control rate using the same or lower dose of radiation (shifting the green
curve to the left). This has to be balanced with monitoring the risk of a normal tissue injury
(not shifting the blue curve to the left). A number of clinical trials, including the work from
Arrieta et al., would suggest that the radiation sensitization is not selective and both curves are
being shifted to the left. For gemcitabine in particular, achieving an acceptable therapeutic
ratio has been more than challenging.
In the first reported study of concurrent gemcitabine and thoracic radiation, the trial
was terminated early after the first eight patients were accrued.2 Although Scalliet et al.
observed an 88% response rate, this study also determined a 75% grade 3 to 4 pneumonitis
rate with 38% patients succumbing to treatment related toxicities. One concern was that
full-dose (1000 mg/m2) gemcitabine weekly was administered with the 60 Gy of thoracic
radiation. Several experiences used moderated doses of gemcitabine and still the concern
for toxicity remains. With preclinical data indicating that gemcitabine possessed radiation
sensitizing properties at much lower doses, Blackstock et al.3 completed a phase Ia/Ib
study of twice-weekly gemcitabine given at a dose of 10 to 50 mg/m2 with 66 to 74 Gy
thoracic radiation. Again, an impressive 88% response rate was observed in the 39 patients
accrued, but grade 3–4 pneumonitis was seen 24% of the patients treated. The first Cancer
and Leukemia Group B (CALGB 9431) study evaluating thoracic radiation and concurrent
gemcitabine, used a dosing scheduled that delivered 350 mg/m2 given on days 1 and 8
every 21 days–not weekly.4 The grade III/IV pneumonitis rate was an acceptable 14%.
This moderate pulmonary toxicity may have to do with the gemcitabine being dosed only
3 to 4 times during the thoracic radiation. However, the 74% response rate and 18.3 month
median survival while encouraging were not interesting enough for further study. In a
subsequent CALGB trial (30105), in which the radiation volumes were prospectively
mandated, 37% of patients receiving concurrent twice-weekly gemcitabine and thoracic
radiation experienced a grade 3 to 5 pulmonary event.5 This arm of the randomized phase
II study was terminated early because of unexpected toxicity. It should be noted that the
V20 (percent of normal lung receiving greater than 20 Gy) for 2 patients experiencing
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grade 5 pulmonary events exceeded 40%; a lung volume that
would be considered excessive by most radiation oncologists.
Data from Zinner et al.6 would support the importance of
the radiation volumes used with gemcitabine. In this phase I
study, the investigators were unable to dose escalate the gem-
citabine until 3-dimensional treatment volumes were mandated.
The Arrietta manuscript does not provide the details of the
thoracic radiation, but one would speculate a relationship be-
tween the normal lung irradiated (V20) and the observed unac-
ceptable pulmonary toxicity. It must be noted that several trials
evaluating this combination of gemcitabine and thoracic radia-
tion have consistently reported high response rates but with
significant nonhematologic toxicities that were not pulmonary.7,8
These manuscripts, however, do not provide a great deal of
detail about the delivery of the radiation in terms of treatment
volumes and V20 restrictions. It seems reasonable that “culpa-
bility” for the narrow therapeutic window of gemcitabine is in
part, that the threshold for toxicity is sensitive to the volume of
normal lung treated.
In retrospect, perhaps we should have anticipated this
strategy had the potential to “go awry” from the preclinical
studies. The radiation sensitizing properties of gemcitabine
have been well described with a number of mechanisms
proposed.9,10 With data from Fields et al.11 suggesting a lower
dose given more frequently provides superior radiation sen-
sitization. However, Mason et al.12 in a jejunal mucosal
animal model was able to demonstrate that gemcitabine
delivered with radiation to normal tissues resulted in a dis-
advantageous shift in the therapeutic ratio, more normal
tissue injury with the combination.
In conclusion, Arrieta et al. provide additional data
indicating gemcitabine delivered concurrent with a course of
definitive thoracic radiation is an active regimen for patients
with stage III non-small cell lung cancer. But these results
and this discussion should remind us that some chemothera-
peutic agents are less forgiving than others as they relate to
normal tissue toxicity. Furthermore, current studies combin-
ing biologics, such as the epidermal growth factor receptor
inhibitors, to standard chemoradiation strategies should be
carefully evaluated, in terms of a potential reversal of the
radiation sensitization properties of the conventional chemo-
therapeutics or for potential unanticipated toxicities.
Moving forward, all clinical trials combining radiation
with radiation sensitizing agents, should mandate detailed
radiation planning parameters and reporting. This represents
our only opportunity for developing the “best laid plans.”
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FIGURE 1. Therapeutic Ratio: The curve for tumor control
is in green and the curve for normal tissue complication is in
blue. With the use of a radiation sensitizer, the hope is for
preferential selection of the tumor tissue shifting that curve
preferentially to the left reducing the risk of normal tissue
complication. Often, there is no selection and both curves
will shift resulting in no relative gain.
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